Professor of Epidemiology and Medicine, Head of Department
Telephone: 01223 748655
Professor Danesh trained in medicine at the University of Otago in New Zealand and at the Royal Melbourne Hospital in Australia. During his time as a Rhodes scholar, he received an MSc in Epidemiology at the London School of Hygiene and Tropical Medicine and a DPhil in Epidemiology at the University of Oxford. He was elected a Fellow of the Royal College of Physicians in 2007.
Since 2001, Danesh has been the Professor of Epidemiology and Medicine at the University of Cambridge. He holds a British Heart Foundation Professorship, a European Research Council Advanced Investigator Award, and an NIHR Senior Investigator Award.
He has the following additional roles:
– Head of the University’s 400-person Department of Public Health and Primary Care
– Director of the Strangeways Research Laboratory
– Director of the Cardiovascular Epidemiology Unit
– Associate Faculty Member at the Wellcome Trust Sanger Institute
– Honorary Consultant at the Cambridge University Hospital NHS Foundation Trust.
Professor Danesh is the founder and director of the Cardiovascular Epidemiology Unit (CEU), a multi-disciplinary Unit of over 60 staff and students that aims to advance understanding and prevention of cardiovascular disease through population health research.
He has published more than 150 papers, which have attracted >15,000 citations. His interests are reflected in the CEU’s main research themes
1) Screening and risk prediction
2) Medicines development
3) International vascular health
4) Gene-lifestyle interplay
5) Systems genomics
6) Blood donor health
7) Quantitative methods
Professor Danesh chairs UK Biobank’s Outcomes Working Group and is a member of the UK Biobank Steering Committee. He is also a member of the national steering committee of the NIHR BioResource.
He is deputy chair of the Wellcome Trust’s Expert Review Group on Genetics / Genomics / Population Research and a member of the MRC’s Population and Systems Medicine Board. He serves on editorial boards, eg: European Journal of Epidemiology, Human Genomics, and international advisory boards, eg: Novartis, Merck, BioScale.
At the local level, he is a member of the Executive Committee of the NIHR Cambridge Biomedical Research Centre, and leads its Population Science programme. He is a member of the Cambridge University Hospital Research Board and of the Steering Committee of the NIHR Cambridge Clinical Trials Unit. He is also a member of the Executive Committee of the Cambridge Institute of Public Health.
Career and Training Possibilities
Professor Danesh is actively involved in the supervision of postgraduate (eg, Masters and PhD) students, and the mentorship of advanced trainees and future research leaders.
Please contact Professor Danesh’s PA to find out more about exciting research and training opportunities in his Unit and Department (see top of page for contact details).
Professor Danesh and the Cardiovascular Epidemiology Unit are supported by programme and project grants from a range of funding agencies, including: the British Heart Foundation, the UK Medical Research Council (MRC), the European Commission, the European Research Council, the Wellcome Trust, US National Institutes of Health, UK National Institute of Health Research, NHS Blood and Transplant, and several industry sources.
The Emerging Risk Factors Collaboration: Kaptoge S…[310 co-authors]…Danesh J. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367:1310-20.
The Emerging Risk Factors Collaboration: Di Angelantonio…[205 co-authors]…Danesh J. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307:2499-2506.
IL6R Genetics Consortium and The Emerging Risk Factors Collaboration: Sarwar N…[352 co-authors]…Danesh J. Interleukin-6 receptor pathways in coronary disease. Lancet 2012;379:1205-1213.
The Emerging Risk Factors Collaboration: Wormser D…[195 other co-authors]…Danesh J. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease. Lancet 2011;377:1085-95.
The Emerging Risk Factors Collaboration: Kondapally Seshasai SR…[286 other co-authors]…Danesh J. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-841.
The Emerging Risk Factors Collaboration: Sarwar N…[296 other co-authors]…Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease. Lancet 2010;375:2215-2222.
The Lp-PLA2 Studies Collaboration: Thompson A…[104 other co-authors]…Danesh J. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke and mortality. Lancet 2010;375:1536–44.
The Emerging Risk Factors collaboration: Kaptoge S…[268 other co-authors]…Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality. Lancet 2010;375:132-40.
The Triglyceride Coronary Disease Genetics Consortium and The Emerging Risk Factors Collaboration: Sarwar N…[251 other co-authors]…Danesh J. Triglyceride-mediated pathways and coronary disease. Lancet 2010;375:1634-9.
The Emerging Risk Factors Collaboration: Erqou S…[268 other co-authors]…Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-423.
*denotes equal contribution